Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05018286 · ClinicalTrials.gov registry record · Phase 3
Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome.
A Phase 3 study of Short Bowel Syndrome, sponsored by VectivBio.
- Active
- Registry status
- Phase 3
- Development phase
- 158
- Enrollment target
- 20
- Study locations
NCT05018286 is a Phase 3 study of Short Bowel Syndrome that is active but no longer recruiting, run by VectivBio. The registered enrollment target is 158 participants, below the 176-participant average among 17 other Short Bowel Syndrome trials with a reported enrollment target (10% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT05018286, a Phase 3 study of Short Bowel Syndrome, is active but no longer recruiting, sponsored by VectivBio.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 158 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of the trial is to assess long-term safety and tolerability of apraglutide in subjects with SBS-IF.
Conditions Studied
Interventions
- DRUG Apraglutide
Study Locations (20)
Other
- University Hospital Fundacion Favaloro - Buenos Aires
- University Hospital Brussels - Brussels
- UZ Leuven - Leuven
- University Hospital Brno - Brno
- University Hospital Hradec Kralove - Hradec Králové
- Hospital Novy Jicin - Nový Jičín
- University Hospital Plzen - Pilsen
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
- Cleveland Clinic Foundation - Cleveland
California
- Ronald Reagan UCLA Medical Center - Los Angeles
Florida
- Gastroenterology Group of Naples - Naples
Illinois
- Northwestern University - Chicago - Chicago
Michigan
- Henry Ford Health System - Detroit
Minnesota
- Mayo Clinic - Rochester - Rochester
Nebraska
- University of Nebraska Medical Center - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 158 participants |
| Start Date | 2021-07-13 |
| Est. Completion | 2027-10-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05018286
The ClinicalTrials.gov registry entry for NCT05018286 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 158 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 176-participant average among 17 other Short Bowel Syndrome trials with a reported enrollment target (10% lower). The listed sponsor is VectivBio, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Short Bowel Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Apraglutide is the first listed.
NCT05018286 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Other, Ohio, California.
Frequently Asked Questions
What is clinical trial NCT05018286 about?
NCT05018286 is a clinical study titled "Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome.". The primary objective of the trial is to assess long-term safety and tolerability of apraglutide in subjects with SBS-IF.
What is the current status of trial NCT05018286?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 158 participants. The study started on 2021-07-13. Estimated completion is 2027-10-30.
What conditions does trial NCT05018286 study?
This clinical trial studies the following conditions: Short Bowel Syndrome.
What interventions are being tested in trial NCT05018286?
The interventions under investigation include: Apraglutide (DRUG).
Who is sponsoring clinical trial NCT05018286?
This trial is sponsored by VectivBio, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05018286 being conducted?
This trial has 20 study locations across California, Florida, Illinois, Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Short Bowel Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS
RECRUITING · Phase 3
-
Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS
ACTIVE NOT RECRUITING · Phase 3
-
Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS - Extension Trial
ACTIVE NOT RECRUITING · Phase 3
-
Trial to Evaluate Efficacy and Safety of Apraglutide in SBS-IF
COMPLETED · Phase 3
-
Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome
COMPLETED · Phase 3
-
Long-term Safety and Efficacy Study of Teduglutide in Pediatric Participants With Short Bowel Syndrome (SBS)
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.